The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma: An Overview of Clinical and Economic Information

Author： Messori Andrea

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.4, 2011-04, pp. : 269-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in multiple myeloma

By García-Sanz Ramón

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

By Chen RA Tu Y Cao Y Liu L Liang Y

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1975-1984

Field House Publishing

Access to resources Recommend Favorite